# Rebecca Kristeleit

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/rebecca-kristeleit/

## Facts

| Field | Value |
| --- | --- |
| Citations | 9,058 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 42 |
| i10-index | 113 |
| Last Known Institution | Guy's and St Thomas' NHS Foundation Trust |
| OpenAlex ID | https://openalex.org/A5088144652 |
| ORCID iD | 0000-0003-3825-1326 |
| Works | 350 |

## Researcher papers

- [Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial](https://scholariq.org/papers/rucaparib-in-relapsed-platinum-sensitive-high-grade-ovarian-carcinoma-ariel2/)
- [Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial](https://scholariq.org/papers/lurbinectedin-as-second-line-treatment-for-patients-with-small-cell-lung-cancer/)
- [Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study](https://scholariq.org/papers/avelumab-alone-or-in-combination-with-chemotherapy-versus-chemotherapy-alone-in/)
- [A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)](https://scholariq.org/papers/a-randomized-phase-iii-trial-to-evaluate-rucaparib-monotherapy-as-maintenance/)
- [First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors](https://scholariq.org/papers/first-in-human-phase-i-study-of-pictilisib-gdc-0941-a-potent-pan-class-i/)
- [Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study](https://scholariq.org/papers/safety-and-antitumor-activity-of-dostarlimab-in-patients-with-advanced-or/)
- [Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2](https://scholariq.org/papers/antitumor-activity-and-safety-of-the-parp-inhibitor-rucaparib-in-patients-with/)
- [Homologous recombination deficiency and ovarian cancer](https://scholariq.org/papers/homologous-recombination-deficiency-and-ovarian-cancer/)
- [A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors](https://scholariq.org/papers/a-phase-i-ii-study-of-the-oral-parp-inhibitor-rucaparib-in-patients-with/)
- [PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions](https://scholariq.org/papers/parp-inhibitors-for-brca1-2-mutated-and-sporadic-ovarian-cancer-current-practice/)
- [Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study](https://scholariq.org/papers/rucaparib-maintenance-for-newly-diagnosed-advanced-ovarian-cancer-interim/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [Histone Deacetylase Inhibitors Research](https://scholariq.org/topics/histone-deacetylase-inhibitors-research/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Guy's and St Thomas' NHS Foundation Trust](https://scholariq.org/institutions/guy-s-and-st-thomas-nhs-foundation-trust/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.